Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA4 | P22748 | 1/20 | 0.53 |
| ▸ | CA6 | P23280 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
| ▸ | TPMT | P51580 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.53 |
| ▸ | PYGL | P06737 | 5/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.48 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.48 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.48 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8508438 | 0.92 | CA12 (0.46) | CA12CA1CA2CA4CA6 | |
| SCHEMBL30362191 | 0.89 | PPARG (0.55) | CA12CA1CA2CA4CA6 | |
| SCHEMBL31104508 | 0.89 | MAPT (0.50) | PYGLHTTABCC9ABCC8KCNJ11 | |
| SCHEMBL3982009 | 0.89 | PPARG (0.55) | CA12CA1CA2CA4CA6 | |
| SCHEMBL11959263 | 0.89 | MAPT (0.50) | PYGLHTTABCC9ABCC8KCNJ11 | |
| SCHEMBL10105362 | 0.86 | CA12 (0.61) | CA12CA1CA2CA4CA6 | |
| SCHEMBL31597010 | 0.86 | ELANE (0.43) | CA12CA1CA2CA4CA6 | |
| SCHEMBL16114813 | 0.86 | TSHR (0.55) | CA12CA1CA2CA4CA6 | |
| SCHEMBL3256083 | 0.85 | NPC1 (0.54) | MEN1KMT2AMAPK1ALDH1A1HPGD | |
| SCHEMBL17047591 | 0.85 | TSHR (0.52) | RAB9ALMNATSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814373-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230312539-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20160032047-A1 | Peg-based adhesive phenylic derivatives and methods of synthesis and use | DSM IP ASSETS B.V. (NL) | 2016-02-04 | — | — | US | disclosed |
| EP-2968667-A1 | PEG-BASED ADHESIVE PHENYLIC DERIVATIVES AND METHODS OF SYNTHESIS AND USE | DSM IP Assets B.V. (NL) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014158288-A1 | PEG-BASED ADHESIVE PHENYLIC DERIVATIVES AND METHODS OF SYNTHESIS AND USE | DSM IP ASSETS B.V. (NL) | 2014-10-02 | — | — | WO | disclosed |
| EP-2424840-B1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2014-08-06 | — | — | EP | disclosed |
| US-8450317-B2 | CXCR3 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-28 | — | — | US | disclosed |
| EP-2424840-A1 | CXCR3 RECEPTOR ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2012-03-07 | — | — | EP | disclosed |
| EP-0986384-B1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIV PITTSBURGH (US) | 2012-02-22 | — | — | EP | disclosed |
| US-20100280028-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-04 | — | — | US | disclosed |
| US-6221865-B1 | INHIBITORS OF PROTEIN FARNESYLTRANSFERASE AND PROTEIN GERANYLGERANYLTRANSFERASE. | UNIVERSITY OF PITTSBURGH | 2001-04-24 | — | — | US | disclosed |
| US-6204293-B1 | INHIBITING POST-TRANSLATIONAL MODIFICATION OF THE ONCOGENIC RAS PROTEIN BY PROTEIN FARNESYLTRANSFERASE, PROTEIN GERANYLGERANYLTRANSFERASE, OR BOTH | UNIVERSITY OF PITTSBURGH | 2001-03-20 | — | — | US | disclosed |
| EP-0986384-A1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 2000-03-22 | — | — | EP | disclosed |
| US-5965539-A | PEPTIDOMIMETICS; ANTI-CANCER DRUGS | UNIVERISTY OF PITTSBURGH (US) | 1999-10-12 | — | — | US | disclosed |
| EP-0794789-A4 | INHIBITORS OF PRENYL TRANSFERASES | UNIV PITTSBURGH (US) | 1999-05-26 | — | — | EP | disclosed |
| WO-1998050029-A1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 1998-11-12 | — | — | WO | disclosed |
| WO-1998050031-A1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 1998-11-12 | — | — | WO | disclosed |
| US-5834434-A | PEPTIDOMIMETICS | UNIVERSITY OF PITTSBURGH (US) | 1998-11-10 | — | — | US | disclosed |
| EP-0794789-A1 | INHIBITORS OF PRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 1997-09-17 | — | — | EP | disclosed |
| WO-1996021456-A1 | INHIBITORS OF PRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 1996-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280028-A1 | CXCR3 RECEPTOR ANTAGONISTS | CXCR3, CXCR1, CXCR2 | CA12 3962/4885CA1 3870/4885CA2 3060/4885 |
| US-20230312539-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, KRAS | CA12 3754/4885CA1 2828/4885CA2 3501/4885 |
| US-11814373-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, KRAS | CA12 3754/4885CA1 2828/4885CA2 3501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.